Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

Nithyapriya M.; S. Purushotaman

doi:10.18203/2319-2003.ijbcp20191097

Authors

Nithyapriya M. Department of Pharmacology, Government Mohan kumara Mangalam Medical College, Salem, Tamil Nadu, India
S. Purushotaman Department of Pharmacology, Department of Pharmacology, Madras Medical College, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20191097

Keywords:

Bromocriptine, Glipizide, Metformin, Type 2 diabetes mellitus

Abstract

Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.

Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1^st, 2^nd and 3^rd month. HbA1C was done at baseline and at the end of 3 months.

Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).

Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

Metrics

Metrics Loading ...

References

Ryan JG. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gender Med. 2009;6:86-108.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501-6.

Deleu D, Northway MG, Hanssens Y. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease. Saudi Med J. 2002;23(10):1165-75.

Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Ind J Pharmacol. 2009;41(4):197.

Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacotherapy. 2010;44(11):1777-85.

Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diab Metab Syndrome Obes Targets Therapy. 2010;3:43.

DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diab Care. 2011;34(4):789-94.

Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes. BMJ. 1993;306(6877):532.

Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opinion Investigational Drugs. 1999;8(10):1683-707.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diab Care. 2000;23(8):1154-61.

Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics?. Hormone Res Paediatrics. 2004;62(2):55-9.

Scranton R, Cincotta A. Bromocriptine–unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opinion Pharmacotherapy. 2010;11(2):269-79.

Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diab Care. 1996;19(6):667-70.

Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial. Ind J Pharmacol. 2014;46(1):24.

Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Ind J Endocrinol Metab. 2011;15(1):17.

American Diabetes Association. Standards of medical care for diabetes. Diab Care. 2008;31(1):S12-54.

Książek A, Załuska W. Sympathetic overactivity in uremia. J Renal Nutrition. 2008;18(1):118-21.

Kagan A, Gertler A, Ulman M, Bar-Khayim Y. Serum levels and peritoneal loss of prolactin in CAPD patients. In: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 1991; 7: 247-252.

Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354-7.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diab Care. 2000;23(8):1154-61.

Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Ind J Endocrinol Metab. 2011;15(1):S33.

Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diab Care. 1997;20(11):1697-701.